Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P46098 (
5-HT3 receptor
)
2,290
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We examined the effects of several protein kinase C (PKC) inhibitors on the murine 5-hydroxytryptamine3 (5-HT3) receptor to determine whether they acted directly on the receptor. The 5-HT-evoked currents in Xenopus laevis oocytes expressing the recombinant
5-HT3 receptor
were measured with the two-electrode voltage-clamp technique. The PKC inhibitors bisindolylmaleimide I (
BIM
, GF109203x) and staurosporine, but not calphostin C or chelerythrine, decreased the
5-HT3 receptor
-mediated currents when coapplied with 5-HT.
BIM
blocked 0.5 microM 5-HT-elicited currents with an IC50 value of 7 nM, whereas in the presence of 5 microM staurosporine, 42% inhibition of 0.5 microM 5-HT-mediated currents was observed. Increasing concentrations of
BIM
resulted in a rightward shift of the 5-HT concentration-response curve, without altering efficacy. A Schild plot was generated, which had a slope of -1.01, suggesting competitive antagonism. The Ki value of
BIM
was determined to be 29 nM. To confirm competitive antagonism, a competitive binding assay was performed on Sf21 insect cells infected with the mouse
5-HT3 receptor
cDNA in a baculovirus expression vector.
BIM
completely displaced binding of the selective
5-HT3 receptor
antagonist [3H]GR65630.
BIM
bound to the
5-HT3 receptor
with a Ki value of 61 nM, which was slightly less potent than that of the selective
5-HT3 receptor
antagonist MDL72222 (27 nM). The PKC inhibitor
BIM
is a potent competitive antagonist at the
5-HT3 receptor
.
...
PMID:Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a "selective" protein kinase C inhibitor. 1038 62